CERO THERAPEUTICS HOLDINGS I (CERO) Forecast, Price Target & Analyst Ratings

NASDAQ:CERO • US71902K4022

Current stock price

0.0951 USD
-1.69 (-94.69%)
At close:
0.12 USD
+0.02 (+26.18%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CERO THERAPEUTICS HOLDINGS I (CERO).

Forecast Snapshot

Consensus Price Target

Price Target
$22.95
+ 24,032.49% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2025
EPS Estimate
-$1.55
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$22.95
Upside
+ 24,032.49%
From current price of $0.10 to mean target of $22.95, Based on 8 analyst forecasts
Low
$15.15
Median
$22.95
High
$31.50

Price Target Revisions

1 Month
-50.00%
3 Months
-50.00%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for CERO. The average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.
The average price target has been revised downward by 50% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CERO Current Analyst RatingCERO Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

CERO Historical Analyst RatingsCERO Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -6 -5 -4 -3 -2 -1 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
CERO was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CERO.
In the previous month the buy percentage consensus was at a similar level.
CERO was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-11-18D. Boral CapitalDowngrade Buy -> Hold
2025-11-03Maxim GroupDowngrade Buy -> Hold
2025-10-30D. Boral CapitalMaintains Buy -> Buy
2025-10-22D. Boral CapitalMaintains Buy -> Buy
2025-10-13D. Boral CapitalMaintains Buy -> Buy
2025-09-23D. Boral CapitalMaintains Buy -> Buy
2025-09-09D. Boral CapitalMaintains Buy -> Buy
2025-09-05D. Boral CapitalMaintains Buy -> Buy
2025-08-04D. Boral CapitalMaintains Buy -> Buy
2025-06-24D. Boral CapitalMaintains Buy -> Buy
2025-06-23D. Boral CapitalUpgrade Hold -> Buy
2025-05-30D. Boral CapitalDowngrade Buy -> Hold
2025-05-19Maxim GroupInitiate Buy
2025-04-25D. Boral CapitalMaintains Buy -> Buy
2025-04-23D. Boral CapitalMaintains Buy -> Buy
2025-04-22D. Boral CapitalInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2025
EPS Estimate
-$1.55
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
N/A
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
83.22%
EPS (3 Months)
83.22%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
CERO revenue by date.CERO revenue by date.
N/AN/AN/AN/AN/AN/A
152.02%		N/A
119.07%		N/A
85.98%
EBITDA
YoY % growth
CERO ebitda by date.CERO ebitda by date.
N/AN/AN/A-15.76MN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CERO ebit by date.CERO ebit by date.
-332K-2.905M
-775.12%		-2.933M
-0.95%		-16.198M
-452.27%		N/A
-12.42%		N/A
-20.22%		N/A
-64.23%		N/A
-18.28%		N/A
-5.00%		N/A
-6.96%		N/A
26.70%		N/A
177.52%
Operating Margin
CERO operating margin by date.CERO operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
CERO eps by date.CERO eps by date.
N/AN/AN/AN/AN/AN/A
38.38%		N/A
1.01%		N/A
87.18%		N/A
-1.45%		N/A
15.71%		N/A
89.83%		N/A
770.83%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-1.55-1.73
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		-4.585M
-4.16%		-4.868M
-132.33%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CERO Yearly Revenue VS EstimatesCERO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M 200M 250M
CERO Yearly EPS VS EstimatesCERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
24.78%
EPS Next 5 Year
14.78%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CERO THERAPEUTICS HOLDINGS I / CERO Forecast FAQ

Can you provide the average price target for CERO THERAPEUTICS HOLDINGS I stock?

8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.

Can you provide the consensus estimates for CERO THERAPEUTICS HOLDINGS I next earnings?

The consensus EPS estimate for the next earnings of CERO THERAPEUTICS HOLDINGS I (CERO) is -1.55 USD and the consensus revenue estimate is 0 USD.

What is the consensus rating for CERO THERAPEUTICS HOLDINGS I (CERO) stock?

The consensus rating for CERO THERAPEUTICS HOLDINGS I (CERO) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.